Back to top
more

Inogen (INGN)

(Real Time Quote from BATS)

$9.20 USD

9.20
185,143

-0.05 (-0.54%)

Updated Jul 22, 2024 09:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Analysts Estimate Penumbra (PEN) to Report a Decline in Earnings: What to Look Out for

Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Inogen (INGN) Q3 Earnings Expected to Decline

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons to Add Inogen (INGN) Stock to Your Portfolio Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Avanos Medical (AVNS) Down 14% Since Last Earnings Report: Can It Rebound?

Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shockwave Medical (SWAV) Up 6.1% Since Last Earnings Report: Can It Continue?

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inogen (INGN) Q2 Earnings and Revenues Beat Estimates

Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.

Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of 95% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?

Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Inogen (INGN) Stock For Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat

Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of 20.83% and 5.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to Inogen (INGN) Stock Now

Inogen (INGN) continues to benefit from strength in the direct-to-customer business model. However, rising costs remain a woe.

Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss

Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.

Inogen (INGN) Reports Q4 Loss, Misses Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of -36.49% and 0.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Avanos Medical (AVNS) Beats Q4 Earnings and Revenue Estimates

Avanos Medical (AVNS) delivered earnings and revenue surprises of 15% and 1.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Inogen (INGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inogen's (INGN) Preliminary Q4 Revenues Solid Amid Challenges

Inogen's (INGN) revenue growth in the fourth quarter is likely to have been boosted by solid product sales despite supply chain constraints.

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

Inogen (INGN) Q3 Earnings and Revenues Surpass Estimates

Inogen (INGN) delivered earnings and revenue surprises of 282.76% and 9.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Inogen (INGN) Stock For Now

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.